Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
125.1 ^USD	+3.01%		+7.81%	+25.83%

15/07	Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	MT
12/07	China approves CSPC Pharma's RSV vaccine for clinical trials	RE

Moderna : European Union medicines agency recommends approval of Moderna Inc.'s COVID-19 vaccine for use in the 27-nation bloc

January 06, 2021 at 05:58 pm IST

THE HAGUE, Netherlands (AP) — European Union medicines agency recommends approval of Moderna Inc.'s COVID-19 vaccine for use in the 27-nation bloc.

Latest news about Moderna, Inc.

Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	15/07	MT
China approves CSPC Pharma's RSV vaccine for clinical trials	12/07	RE
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation	10/07	MT
Redburn Raises Moderna's Price Target to $117 From $116	10/07	MT
Bird flu response in Michigan sparks COVID-era worry on farms	10/07	RE
Moderna: partnership for mRNA vaccines in Japan	09/07	CF
Moderna Partners With Mitsubishi Tanabe Pharma to Promote Vaccines in Japan	09/07	MT
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines	09/07	CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	08/07	RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	08/07	RE
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	02/07	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	02/07	MT
Moderna: grant for influenza vaccine	02/07	CF
Moderna Receives $176 Million Award to Boost Development of mRNA-Based Pandemic Flu Vaccine	02/07	MT
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case	02/07	RE
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion'	01/07	RE
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Value-Defensive Index	01/07	CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Defensive Index	01/07	CI
Moderna: positive CHMP opinion on RSV	28/06	CF
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	28/06	MT
Sector Update: Health Care Stocks Higher Pre-Bell Friday	28/06	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Report	28/06	MT
Sector Update: Health Care	28/06	MT
Moderna Secures European Medicines Agency's Positive Opinion for mRESVIA	28/06	MT
European Medical Agency's Committee Backs Moderna's RSV Vaccine	28/06	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says

June 13, 2024 at 01:08 am IST

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 07:54 pm IST

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 17, 2024 at 02:01 am IST

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

121.5 USD

Average target price

145.9 USD

Spread / Average Target

+20.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.85%	11.14B

Other Biotechnology & Medical Research

Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Moderna : European Union medicines agency recommends approval of Moderna Inc.'s COVID-19 vaccine for use in the 27-nation bloc

Latest news about Moderna, Inc.

Chart Moderna, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Moderna, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research